A5033610093- Veterinary Oncology Research
- Virus-based gene therapy research
- Fibroblast Growth Factor Research
- Cardiovascular Conditions and Treatments
- Immune cells in cancer
University of Wisconsin–Madison
2019-2021
This study is a concurrent comparison of two versions CHOP protocols, 19-week and comparatively overall dose-intense 12-week CHOP. The protocol was designed to be 58% more dose intense than the for both doxorubicin cyclophosphamide; however, it 21% less vincristine (VCR). Forty-seven dogs were included evaluation, characteristics each population similar. For receiving protocol, 89.5% experienced complete response, with median progression-free survival (PFS) 245 days (OS) 347 days. 89.3% PFS...
Abstract OBJECTIVE To determine whether, in dogs with naïve multicentric lymphoma, neutrophilia at the time of initial diagnosis was associated progression-free survival (PFST) or overall response rate (ie, percentage a complete partial remission) and whether neutrophil-to-lymphocyte ratio PFST. ANIMALS 30 lymphoma (including 16 treated cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP]–based protocol) 37 historical control without CHOP-based protocol. PROCEDURES Medical records...